Try our Advanced Search for more refined results

FTC Targets AbbVie, Teva In 1st New Pay-For-Delay Suit

By Melissa Lipman ( September 8, 2014, 8:22 PM EDT) -- The Federal Trade Commission accused AbbVie Inc. on Monday of keeping Teva Pharmaceuticals USA Inc.'s generic AndroGel off the market through a side licensing deal, and experts say the watchdog's first pay-for-delay case since its 2013 U.S. Supreme Court win is already stretching the boundaries the justices laid out for antitrust claims under that landmark decision....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Subscribers Only

Nature of Suit

Subscribers Only

Judge

Subscribers Only

Date Filed

Subscribers Only

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!